Public Release:  Common invasive test not necessary for kidney disease patients

Clinicians can monitor kidney function with a simple equation

American Society of Nephrology

Washington, DC (September 15, 2011) -- Equations that estimate a patient's kidney function work as well as direct, invasive measurements, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). This means that many patients with chronic kidney disease (CKD) do not need to undergo the painful and cumbersome procedures that are performed to monitor kidneys' health.

Measuring CKD patients' kidney function can help physicians anticipate complications and provide optimal treatments. Most measures focus on patients' glomerular filtration rate (GFR), or the rate that the kidneys filter wastes from the urine. Clinicians have traditionally assumed that directly testing GFR by injecting a tracer agent such as iothalamate provides a better measure of kidney function than calculating GFR indirectly with an equation. However, iothalamate GFR (iGFR) is more cumbersome and invasive than equation-estimated GFR (eGFR). Specifically, iGFR involves injecting a (sometimes radioactive) agent, taking multiple blood samples, and doing timed urine collections, while eGFR involves one simple blood test.

To compare the tests, Chi-yuan Hsu, MD (University of California, San Francisco) and his colleagues looked to see which is more strongly and consistently linked with common CKD complications in 1,214 CKD patients who participated in the Chronic Renal Insufficiency Cohort (CRIC) study, which includes the largest ever group of CKD patients assembled and is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.

The investigators found that eGFR linked just as tightly to CKD complications as iGFR. These results refute the conventional view that iGFR is in fact the gold standard measure of kidney function. "For many purposes and for many patients, relying on equations to estimate GFR alone may be sufficient, and patients can avoid undergoing more invasive assays to directly measure GFR," said Dr. Hsu.

###

Approximately 60 million people globally have CKD. Early detection and treatment can prevent kidney failure, but individuals with the disease often do not experience symptoms until later stages.

Study co-authors include Kathleen Propert, PhD, Dawei Xie, PhD, Valerie Teal, Raymond Townsend, MD, Harold Feldman, MD (University of Pennsylvania); Lee Hamm, MD, Jiang He, MD, PhD (Tulane University); Edgar Miller, MD (Johns Hopkins University); Akinlolu Ojo, MD, PhD, Jillian Wilson (University of Michigan, Ann Arbor); Michael Shlipak, MD (University of California, San Francisco); and Matthew Weir, MD (University of Maryland).

Disclosures: The authors reported no financial disclosures.

The article, entitled "Is iGFR Really Better than eGFR? Analyzing Associations with Common Co-morbid Conditions," will appear online at http://jasn.asnjournals.org/ doi 10.1681/ASN.2010101077

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 13,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.